Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States

Patients treated with semaglutide had lower all-cause and ORC-related total medical costs than non-users, with a yearly reduction of $3,870 and $3,482, respectively. Cost reductions were driven by significantly lower inpatient hospitalization rates and costs.